Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of 4.80 is 1741% above its 3-year average of -0.29, near the high end of its 3-year range (-10.88–4.80).
As of the fiscal period ended Tuesday, June 30, 2026. 430.13% above its 12-month average of -1.45.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 4.80.
DEBT TO EQUITY RATIO
4.80
DEBT TO EQUITY RATIO AVG TTM
-1.45
DEBT TO EQUITY RATIO AVG 3Y
-0.29
DEBT TO EQUITY RATIO AVG 5Y
N/A
DEBT TO EQUITY RATIO AVG 10Y
N/A
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+430.13%
CURRENT VS 3Y AVG
+1740.69%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.13
median of 570 covered companies
CURRENT VS SECTOR MEDIAN
+3591.19%
vs the sector median at left
Liminatus Pharma, Inc. Class A Common Stock
Market Cap
$5.23M
Debt to Equity Ratio
4.80
TTM Avg
-1.45
3Y Avg
-0.29
5Y Avg
N/A
Market Cap
$5.21M
Debt to Equity Ratio
N/A
TTM Avg
0.07
3Y Avg
0.07
5Y Avg
0.07
Market Cap
$5.26M
Debt to Equity Ratio
0.33
TTM Avg
0.21
3Y Avg
0.27
5Y Avg
0.18
Market Cap
$5.17M
Debt to Equity Ratio
0.36
TTM Avg
0.26
3Y Avg
0.18
5Y Avg
0.25
Market Cap
$5.36M
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.03
Market Cap
$5.03M
Debt to Equity Ratio
1.57
TTM Avg
0.64
3Y Avg
1.33
5Y Avg
1.33
Market Cap
$5.57M
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.00
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Liminatus Pharma, Inc. Class A Common Stock (LIMN) | $5.23M | 4.80 | -1.45 | -0.29 | N/A |
| Lunai Bioworks Inc. (LNAI)vs › | $5.21M | N/A | 0.07 | 0.07 | 0.07 |
| Intelligent Bio Solutions Inc. (INBS)vs › | $5.26M | 0.33 | 0.21 | 0.27 | 0.18 |
| Gelteq Limited Ordinary Shares (GELS)vs › | $5.17M | 0.36 | 0.26 | 0.18 | 0.25 |
| Alzamend Neuro Inc (ALZN)vs › | $5.36M | 0.00 | 0.00 | 0.00 | 0.03 |
| Imunon, Inc. (IMNN)vs › | $5.11M | 1.87 | 0.21 | 0.18 | 0.20 |
| Basel Medical Group Ltd Ordinary Shares (BMGL)vs › | $5.03M | 1.57 | 0.64 | 1.33 | 1.33 |
| Acurx Pharmaceuticals, Inc. (ACXP)vs › | $5.57M | 0.00 | 0.00 | 0.00 | 0.00 |
| CalciMedica, Inc. (CALC)vs › | $4.91M | 0.00 | 0.00 | 0.00 | 0.92 |
| Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR)vs › | $5.68M | 0.10 | 0.10 | 0.10 | 0.10 |
Debt/Equity
4.80
Current Ratio
1.12
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | 4.80 |
| 2026-03-31 | -10.88 |
| 2025-12-31 | -0.15 |
| 2025-09-30 | -0.88 |
| 2025-06-30 | -0.16 |
| 2025-03-31 | 0.00 |
| 2024-12-31 | -0.32 |
| 2024-09-30 | -0.32 |
| 2024-06-30 | -0.29 |
| 2024-03-31 | -0.34 |
| 2023-12-31 | -1.50 |
| 2023-09-30 | -0.17 |
